Premium
Albumin‐Assisted Method Allows Assessment of Release of Hydrophobic Drugs From Nanocarriers
Author(s) -
Gil Dmitry,
FrankKamenetskii Anastasia,
Barry John,
Reukov Vladimir,
Xiang Yun,
Das Arabinda,
Varma Abhay K.,
Kindy Mark S.,
Banik Naren L.,
Vertegel Alexey
Publication year - 2018
Publication title -
biotechnology journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.144
H-Index - 84
eISSN - 1860-7314
pISSN - 1860-6768
DOI - 10.1002/biot.201700337
Subject(s) - nanocarriers , chemistry , drug , bovine serum albumin , liposome , drug delivery , albumin , in vivo , drug carrier , serum albumin , chromatography , pharmacology , biochemistry , organic chemistry , medicine , microbiology and biotechnology , biology
Polymeric nanoparticles have been extensively studied as drug delivery vehicles both in vitro and in vivo for the last two decades. In vitro methods to assess drug release profiles usually utilize degradation of nanoparticles in aqueous medium, followed by the measurement of the concentration of the released drug. This method, however, is difficult to use for drugs that are poorly water soluble. In this study, a protocol for measuring drug release kinetic using albumin solution as the medium is described. Albumin is a major blood transport protein, which mediates transport of many lipid soluble compounds including fatty acids, hormones, and bilirubin. The use of a dialysis‐based system utilizing albumin dialysate solution allows hydrophobic drug release from a diverse set of drug delivery modalities is demonstrated. The method using liposomes and PLGA nanoparticles as drug carriers, and two model hydrophobic drugs, 17β‐estradiol, and dexamethasone is validated.